Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Express Scripts
Baxter
Dow
Moodys
McKesson
Medtronic

Last Updated: June 29, 2022

CLINICAL TRIALS PROFILE FOR BENDEKA


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Bendeka

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01286272 ↗ Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma Active, not recruiting National Cancer Institute (NCI) Phase 2 2011-04-08 This randomized phase II trial studies how well ofatumumab and bendamustine hydrochloride with or without bortezomib works in treating patients with untreated follicular non-Hodgkin lymphoma. Monoclonal antibodies, such as ofatumumab, may block cancer growth in different ways by targeting certain cells. Drugs used in chemotherapy, such as bendamustine hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Bortezomib may also stop the growth of cancer cells by blocking blood flow to the tumor. It is not yet known whether ofatumumab and bendamustine hydrochloride are more effective with bortezomib in treating patients with follicular non-Hodgkin lymphoma.
NCT01754402 ↗ Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma Active, not recruiting Celgene Phase 1/Phase 2 2013-01-07 This study is designed as a phase I-II, open label, dose finding study. Study treatment will be as follows, in 28 day cycles: - Pomalidomide: once daily orally (PO) dosing on days 1-21, every 28 days - Bendamustine: once intravenously (IV) dosing on day 1, every 28 days - Dexamethasone: weekly PO or IV dosing on days 1, 8, 15, and 22. After completing 6 cycles of treatment, dexamethasone may be decreased to 20mg per investigator discretion. After completing 12 cycles of treatment, patients will proceed to the maintenance phase of the study. Patients will receive Pomalidomide on day 1-21, every 28 days and dexamethasone on days 1, 8, 15, and 22 every 28 days until time of progression.
NCT01754402 ↗ Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma Active, not recruiting Cristina Gasparetto Phase 1/Phase 2 2013-01-07 This study is designed as a phase I-II, open label, dose finding study. Study treatment will be as follows, in 28 day cycles: - Pomalidomide: once daily orally (PO) dosing on days 1-21, every 28 days - Bendamustine: once intravenously (IV) dosing on day 1, every 28 days - Dexamethasone: weekly PO or IV dosing on days 1, 8, 15, and 22. After completing 6 cycles of treatment, dexamethasone may be decreased to 20mg per investigator discretion. After completing 12 cycles of treatment, patients will proceed to the maintenance phase of the study. Patients will receive Pomalidomide on day 1-21, every 28 days and dexamethasone on days 1, 8, 15, and 22 every 28 days until time of progression.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Bendeka

Condition Name

Condition Name for Bendeka
Intervention Trials
Recurrent Follicular Lymphoma 3
Mantle Cell Lymphoma 3
Multiple Myeloma 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Bendeka
Intervention Trials
Lymphoma 14
Leukemia, Lymphoid 5
Leukemia, Lymphocytic, Chronic, B-Cell 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Bendeka

Trials by Country

Trials by Country for Bendeka
Location Trials
United States 189
Canada 8
Germany 2
Vietnam 1
Czechia 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Bendeka
Location Trials
North Carolina 9
Texas 8
Missouri 8
California 8
South Carolina 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Bendeka

Clinical Trial Phase

Clinical Trial Phase for Bendeka
Clinical Trial Phase Trials
Phase 3 4
Phase 2 10
Phase 1/Phase 2 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Bendeka
Clinical Trial Phase Trials
Recruiting 11
Active, not recruiting 6
Not yet recruiting 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Bendeka

Sponsor Name

Sponsor Name for Bendeka
Sponsor Trials
National Cancer Institute (NCI) 9
UNC Lineberger Comprehensive Cancer Center 2
Acerta Pharma BV 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Bendeka
Sponsor Trials
Other 14
Industry 13
NIH 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Medtronic
AstraZeneca
Baxter
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.